Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168090145> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2168090145 endingPage "43.e120" @default.
- W2168090145 startingPage "43.e120" @default.
- W2168090145 abstract "Immuno-therapeutic techniques for cancer were dramatic progress year by year. However, it was limited in efficacy of those. As a reason for it, regulatory T cell (Treg, CD4+/CD25+), which cells depress anti-tumor activity of T-cells in patients with cancer, was detected. On the other hand, it was observed that CTLs (CD8+) produced IFN when CTLs recognized tumor cells. In this study, we investigate therapeutic efficacy of combination therapy using CTLs (CD8+/IFN) and anti-CD25 mAb in the tumor-bearing immunocompetent animals. The RenCa (murine renal carcinoma line originated from Balb/c) xenografted mice were used as animal model. Anti-CD25 IL-2Ra mAb from hybridoma PC61 was used to deplete CD25+ cells. In vivo depletion was performed using a modification of the procedure of Onizuka et al. Mice received 250 μg of anti-CD25 mAb inoculated intraperitoneally. Tumor-bearing mice were divided into 4 administration groups: (1) whole spleen lymphocyte from tumor-bearing mice, (2) CTLs (CD8+/IFN) separated from spleen cells of tumor-bearing mice, (3) anti-CD25 mAb, (4) anti-CD25 mAb and CTLs. In group (4), CTLs were administrated into tumor-bearing mice at 1 week after treatment of anti-CD25 mAb. CTLs (CD8+/IFN) were separated from spleen cells of tumor-bearing mice using sorting system of BD FACS Vantage SE. All of mice in group (1) and (2) were death until 4 weeks after treatment in the same as untreated control mice. In group (3), tumors were disappeared in all mice at 2 days after treatment, but re-growing were observed at 5 weeks after treatment. In contrast, in group (4), tumors were disappeared in all mice at 2 days after treatment and not observed re-growing at 5 weeks after treatment. A combination of the Treg-depletion using anti-CD25 mAb and CTL administration is a feasible approach in the treatment of cancer and should be further explored in the clinic." @default.
- W2168090145 created "2016-06-24" @default.
- W2168090145 creator A5032583722 @default.
- W2168090145 date "2007-09-01" @default.
- W2168090145 modified "2023-09-25" @default.
- W2168090145 title "Poster 216: Combination of CTLs (CD8+/IFN) Reacted With Tumor Cells and Anti-CD25 mAb Provides Improved Immunotherapy for Tumors: An Animal Study" @default.
- W2168090145 cites W2077775725 @default.
- W2168090145 cites W2078718900 @default.
- W2168090145 cites W2147350757 @default.
- W2168090145 cites W2150678612 @default.
- W2168090145 cites W2561377267 @default.
- W2168090145 doi "https://doi.org/10.1016/j.joms.2007.06.485" @default.
- W2168090145 hasPublicationYear "2007" @default.
- W2168090145 type Work @default.
- W2168090145 sameAs 2168090145 @default.
- W2168090145 citedByCount "0" @default.
- W2168090145 crossrefType "journal-article" @default.
- W2168090145 hasAuthorship W2168090145A5032583722 @default.
- W2168090145 hasBestOaLocation W21680901451 @default.
- W2168090145 hasConcept C154317977 @default.
- W2168090145 hasConcept C159654299 @default.
- W2168090145 hasConcept C167672396 @default.
- W2168090145 hasConcept C189976730 @default.
- W2168090145 hasConcept C202751555 @default.
- W2168090145 hasConcept C203014093 @default.
- W2168090145 hasConcept C2776090121 @default.
- W2168090145 hasConcept C2777701055 @default.
- W2168090145 hasConcept C2780931953 @default.
- W2168090145 hasConcept C502942594 @default.
- W2168090145 hasConcept C542903549 @default.
- W2168090145 hasConcept C55493867 @default.
- W2168090145 hasConcept C71924100 @default.
- W2168090145 hasConcept C79484868 @default.
- W2168090145 hasConcept C86803240 @default.
- W2168090145 hasConcept C8891405 @default.
- W2168090145 hasConceptScore W2168090145C154317977 @default.
- W2168090145 hasConceptScore W2168090145C159654299 @default.
- W2168090145 hasConceptScore W2168090145C167672396 @default.
- W2168090145 hasConceptScore W2168090145C189976730 @default.
- W2168090145 hasConceptScore W2168090145C202751555 @default.
- W2168090145 hasConceptScore W2168090145C203014093 @default.
- W2168090145 hasConceptScore W2168090145C2776090121 @default.
- W2168090145 hasConceptScore W2168090145C2777701055 @default.
- W2168090145 hasConceptScore W2168090145C2780931953 @default.
- W2168090145 hasConceptScore W2168090145C502942594 @default.
- W2168090145 hasConceptScore W2168090145C542903549 @default.
- W2168090145 hasConceptScore W2168090145C55493867 @default.
- W2168090145 hasConceptScore W2168090145C71924100 @default.
- W2168090145 hasConceptScore W2168090145C79484868 @default.
- W2168090145 hasConceptScore W2168090145C86803240 @default.
- W2168090145 hasConceptScore W2168090145C8891405 @default.
- W2168090145 hasIssue "9" @default.
- W2168090145 hasLocation W21680901451 @default.
- W2168090145 hasOpenAccess W2168090145 @default.
- W2168090145 hasPrimaryLocation W21680901451 @default.
- W2168090145 hasRelatedWork W1611619657 @default.
- W2168090145 hasRelatedWork W2023330742 @default.
- W2168090145 hasRelatedWork W2054518906 @default.
- W2168090145 hasRelatedWork W2070531919 @default.
- W2168090145 hasRelatedWork W2345222578 @default.
- W2168090145 hasRelatedWork W2381667282 @default.
- W2168090145 hasRelatedWork W2400115325 @default.
- W2168090145 hasRelatedWork W2410889971 @default.
- W2168090145 hasRelatedWork W2470704817 @default.
- W2168090145 hasRelatedWork W3030217861 @default.
- W2168090145 hasVolume "65" @default.
- W2168090145 isParatext "false" @default.
- W2168090145 isRetracted "false" @default.
- W2168090145 magId "2168090145" @default.
- W2168090145 workType "article" @default.